Skip to Content

Join the 'Invokana' group to help and get support from people like you.

Invokana News

Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors

THURSDAY, Sept. 24, 2020 – For individuals with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors are associated with a reduced risk for cardiovascular events during short-term...

Short-Term Risk for Below-Knee Amputation Not Increased With SGLT2i

FRIDAY, Aug. 7, 2020 – For patients with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors do not increase the risk for below-knee amputation compared with dipeptidyl peptidase 4...

In Rare Cases, Diabetes & Cholesterol Drug Combo Could Be Toxic

MONDAY, Aug. 3, 2020 – Taking the statin Crestor in combination with the diabetes drug canagliflozin (Invokana) may have the potential to trigger statin toxicity, a new case report suggests....

SGLT-2 Inhibitors May Raise Risk for Diabetic Ketoacidosis

WEDNESDAY, July 29, 2020 – In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with an increased risk for diabetic ketoacidosis (DKA), according to a...

SGLT2 Inhibitors Commonly Used for Diabetes Linked to Higher Odds for a Serious Complication

TUESDAY, July 28, 2020 – People taking a class of diabetes medications called SGLT2s have up to three times the risk for a serious complication called diabetic ketoacidosis (DKA) compared to people...

SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events

FRIDAY, May 1, 2020 – Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors, according...

FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes and DKD

RARITAN, N.J., Sept. 30, 2019 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for...

SGLT2 Inhibitors for Diabetes Linked to Rare 'Flesh-Eating' Genital Infection

MONDAY, May 6, 2019 – Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease – but one day you notice pain, redness and a foul odor in your genital area....

Common Diabetes Drug Canagliflozin May Also Shield Kidneys, Heart

MONDAY, April 15, 2019 – A common diabetes drug may also greatly reduce the odds for death from kidney failure and heart disease in diabetes patients with kidney disease, a new study finds. The news...

Study Eases Concern That Common Diabetes Drug Canagliflozin (Invokana, Invokamet) Might Harm Bones

THURSDAY, Jan. 3, 2019 – If you have type 2 diabetes and you're taking canagliflozin to help control your blood sugar, a new study has some good news for you: The drug doesn't appear to raise the...

SGLT2 Inhibitors for Diabetes Linked to Increased Risk for Amputation

THURSDAY, Nov. 15, 2018 – A specific class of diabetes medication appears to double the risk of losing a leg or foot to amputation, a new study reports. People on sodium-glucose cotransporter2...

FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

TITUSVILLE, NJ, October 30, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Invokana (canagliflozin) to r...

FDA Warns of Common Diabetes Meds', SGLT2 Inhibitors, Link to Dangerous Genital Infection

THURSDAY, Aug. 30, 2018 – Rare but serious genital infections, as well as one death, have been reported in some patients taking a certain class of type 2 diabetes medicine, the U.S. Food and Drug...

FDA Medwatch Alert: SGLT2 (sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

ISSUE: FDA is warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose...

Primary Care Doctors Loosen Type 2 Diabetes Goals

TUESDAY, March 6, 2018 – The American College of Physicians (ACP) has issued new guidance on managing type 2 diabetes – including relaxing the long-term blood sugar target called hemoglobin A1C....

Ask a Question

Want to post your own question to this support group? You'll need to first create an account with Drugs.com (or sign in to your existing account).

Further Information

Related Condition Support Groups

Cardiovascular Risk Reduction, Diabetes, Type 2

Invokana Patient Information at Drugs.com